Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SUMATRIPTAN; NAPROXEN SODIUM vs RIZATRIPTAN BENZOATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sumatriptan is a selective 5-HT1B/1D receptor agonist, causing vasoconstriction of cranial blood vessels and inhibition of trigeminal nerve transmission. Naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.
Selective serotonin 5-HT1B/1D receptor agonist; binds with high affinity to 5-HT1B and 5-HT1D receptors, leading to vasoconstriction of intracranial blood vessels and inhibition of trigeminal nerve transmission, thereby reducing migraine-associated neurogenic inflammation.
Acute treatment of migraine attacks with or without aura in adults
Acute treatment of migraine with or without aura in adults.,Acute treatment of migraine with or without aura in pediatric patients 6 to 17 years of age.
Sumatriptan 85 mg / naproxen sodium 500 mg orally at onset of migraine; may repeat once after 2 hours if needed, not to exceed 2 tablets in 24 hours.
5-10 mg orally at onset of migraine; may repeat after 2 hours if headache recurs; maximum 30 mg in 24 hours.
Sumatriptan: terminal half-life approximately 2.5 hours (range 1.5–4.6 hours); clinically, short half-life limits duration of action. Naproxen sodium: terminal half-life approximately 12–17 hours (mean 14 hours); long half-life allows twice-daily dosing and sustained analgesic effect.
2-3 hours in adults; clinically, no significant accumulation with multiple dosing.
Sumatriptan is primarily metabolized by monoamine oxidase A (MAO-A). Naproxen is metabolized by CYP2C9.
Primarily metabolized by monoamine oxidase A (MAO-A) via oxidative deamination; minor metabolism by aldehyde oxidase. The major metabolite is the inactive N-desmethyl rizatriptan.
Sumatriptan: renal excretion of unchanged drug and metabolites (primarily indole acetic acid analogue) accounts for approximately 60% of elimination; fecal/biliary excretion accounts for about 40%. Naproxen sodium: renal excretion of unchanged drug (approximately 60%) and glucuronide conjugates (about 40%); less than 5% is excreted fecally.
Primarily hepatic metabolism via monoamine oxidase-A, with ~14% excreted unchanged in urine; total recovery of radioactivity in urine is ~82% (30% unchanged drug, 52% metabolites) and ~9% in feces over 24 hours.
Sumatriptan: protein binding approximately 14–21% (low binding). Naproxen sodium: protein binding >99% (highly bound to albumin).
14%
Sumatriptan: Vd approximately 2.2 L/kg (indicates extensive tissue distribution). Naproxen sodium: Vd approximately 0.16 L/kg (low Vd, consistent with high protein binding and limited tissue distribution).
140 L (approximately 2 L/kg in adults), indicating extensive tissue distribution.
Sumatriptan: oral bioavailability approximately 15% (due to first-pass metabolism); subcutaneous injection 96%; intranasal approximately 17%. Naproxen sodium: oral bioavailability >95% (well absorbed).
Oral: ~45% (due to first-pass metabolism); intranasal: ~42% (compared to subcutaneous sumatriptan); orally disintegrating tablet: ~45%.
Contraindicated if GFR <30 m L/min; for GFR 30-50 m L/min, caution with naproxen component; no specific dose adjustment recommended for sumatriptan.
No dosage adjustment required for mild to moderate renal impairment. Not recommended in severe renal impairment (Cr Cl <30 m L/min) due to limited data.
Contraindicated in severe hepatic impairment (Child-Pugh class C); sumatriptan maximum dose 50 mg per dose in moderate impairment (Child-Pugh class B); naproxen sodium avoid in severe impairment.
Not recommended in patients with severe hepatic impairment (Child-Pugh class C) due to absence of studies. For mild to moderate impairment (Child-Pugh A or B), no specific dose adjustment; use caution.
Not approved for patients <12 years; for adolescents 12-17 years, single dose of sumatriptan 85 mg / naproxen sodium 500 mg (as adult formulation) per clinical judgment, not to exceed 1 dose in 24 hours.
Children 6-17 years: 5-10 mg orally at onset; may repeat after 2 hours; maximum 30 mg per 24 hours. Weight <40 kg: start 5 mg. Weight ≥40 kg: may use 10 mg.
Avoid use in elderly due to increased risk of cardiovascular events, gastrointestinal bleeding, and renal impairment; if necessary, use lowest effective dose for shortest duration.
Elderly patients may have increased risk of adverse effects. Start at 5 mg; use caution with comorbidities and concomitant medications. No specific dose adjustment required; monitor cardiovascular status.
Cardiovascular and gastrointestinal risks: NSAIDs increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk increases with duration of use. NSAIDs also increase the risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. Sumatriptan is contraindicated in patients with history of coronary artery disease or risk factors. Do not use within 24 hours of another 5-HT1 agonist or ergotamine-containing medication.
None
Cardiovascular events: Myocardial ischemia, infarction, arrhythmia, and death reported with sumatriptan. NSAIDs increase risk of serious cardiovascular thrombotic events.,Gastrointestinal effects: NSAIDs increase risk of GI bleeding, ulceration, and perforation.,Excessive use: Medication overuse headache may occur.,Serotonin syndrome: Risk with concurrent use of serotonergic drugs.,Renal effects: NSAIDs can cause renal toxicity.,Hypertension: Sumatriptan may increase blood pressure.,Anaphylactic reactions: Serious allergic reactions including anaphylaxis reported with sumatriptan.,Hepatic effects: NSAIDs may cause liver enzyme elevations.
Risk of myocardial ischemia and/or infarction, coronary artery vasospasm, cerebrovascular events, and increased blood pressure. Serotonin syndrome (especially when co-administered with other serotonergic drugs). Use only after clear diagnosis of migraine; not for use in hemiplegic or basilar migraine. Caution in patients with risk factors for coronary artery disease. Avoid use within 24 hours of other 5-HT1 agonists or ergotamine derivatives. Monitor for signs/symptoms of serotonin syndrome.
History of coronary artery disease (CAD) or coronary artery vasospasm,Wolff-Parkinson-White syndrome or other cardiac accessory pathway disorders,History of stroke or transient ischemic attack,Peripheral vascular disease,Ischemic bowel disease,Uncontrolled hypertension,Within 24 hours of treatment with another 5-HT1 agonist (e.g., triptans) or ergotamine-containing medications,Concomitant use or within 2 weeks of MAO-A inhibitor,History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,In the setting of coronary artery bypass graft (CABG) surgery,Third trimester of pregnancy
History of ischemic heart disease (angina, myocardial infarction, silent ischemia), coronary artery vasospasm (Prinzmetal's angina), or other significant cardiovascular disease. Uncontrolled hypertension. Hemiplegic or basilar migraine. Use within 24 hours of another 5-HT1 agonist or ergotamine-containing medication. Concurrent use or within 2 weeks of monoamine oxidase inhibitor (MAOI) therapy. Known hypersensitivity to rizatriptan or any component. Severe hepatic impairment (Child-Pugh class C).
Avoid alcohol (may exacerbate migraine and increase GI irritation). Limit caffeine intake (can trigger migraine). No specific food restrictions, but maintain hydration.
No significant food interactions. However, high-fat meals may delay absorption. Avoid alcohol as it may worsen headaches or increase side effects.
Sumatriptan: Limited data; no increased risk of major congenital malformations observed in cohort studies. Avoid use in third trimester due to potential uterine vasoconstriction and reduced placental perfusion. Naproxen: First trimester – potential increased risk of cardiac defects; second trimester – generally safe with caution; third trimester – contraindicated due to risk of premature ductus arteriosus closure, oligohydramnios, and fetal renal dysfunction.
Rizatriptan is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, rizatriptan was not teratogenic in rats or rabbits but was associated with embryo-fetal toxicity at maternotoxic doses. Use only if potential benefit justifies potential risk to the fetus. First trimester: no specific data, but theoretical risk of vasoconstriction. Second and third trimesters: may cause uterine contractions or reduced uterine blood flow.
Sumatriptan: Excreted in breast milk with estimated relative infant dose of 3.5% of maternal weight-adjusted dose; M/P ratio not well defined. Naproxen: Excreted in breast milk with M/P ratio approximately 0.01; relative infant dose <1% of maternal dose. Both considered compatible with breastfeeding with monitoring for infant adverse effects.
Rizatriptan is excreted in human milk at very low levels; the milk-to-plasma ratio is approximately 0.07. The estimated infant dose is about 3% of the maternal weight-adjusted dose. Caution is advised; consider the developmental and health benefits of breastfeeding along with the mother's clinical need for rizatriptan and potential adverse effects on the breastfed infant.
No specific dose adjustments recommended for sumatriptan in pregnancy; however, limited data suggest no significant pharmacokinetic changes. Naproxen: Clearance may increase in later pregnancy; dose adjustments not well studied. Avoid naproxen in third trimester.
No specific dose adjustments are recommended for pregnancy; however, pharmacokinetic changes in pregnancy (increased plasma volume, altered metabolism) may reduce exposure. Use lowest effective dose for shortest duration. If migraine severity warrants, standard dosing (5-10 mg oral, may repeat after 2 hours, max 30 mg/24h) may be used.
Sumatriptan/naproxen sodium is contraindicated within 24 hours of another triptan or ergotamine. Naproxen dose is fixed; avoid additional NSAIDs to prevent GI bleeding or renal impairment. Use with caution in patients with cardiovascular risk factors. Onset of action is 10-30 minutes; advise against driving if dizziness occurs.
Rizatriptan is a selective 5-HT1B/1D receptor agonist used for acute migraine. Onset of action is rapid (30 min). Maximum daily dose is 30 mg (oral tablets) or 30 mg (ODT). Do not use within 24 hours of other triptans or ergotamines. Contraindicated in patients with ischemic heart disease, uncontrolled hypertension, or basilar/hemiplegic migraine. Avoid in patients with moderate/severe hepatic impairment. ODT dissolves quickly and can be taken without water, useful for patients with nausea.
Take at the first sign of migraine; do not exceed one tablet in 24 hours.,Do not take within 24 hours of other triptans or ergotamine-containing drugs.,Avoid alcohol during migraine attack as it may worsen symptoms.,Report chest tightness, palpitations, or shortness of breath immediately.,Do not drive or operate machinery if feeling dizzy or drowsy.,Inform healthcare provider of all medications, especially blood thinners or antidepressants.
Take at the first sign of migraine headache; it will not prevent attacks.,Do not exceed 30 mg in any 24-hour period (separate doses by at least 2 hours).,If first dose does not work, do not take a second dose for the same attack without consulting your doctor.,Seek emergency care if you experience chest pain, shortness of breath, or sudden severe headache.,Inform your doctor if you have heart disease, high blood pressure, or are taking MAOIs (within 2 weeks) or other migraine medications.
"Naproxen and meloxicam are both nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase (COX) enzymes, leading to decreased synthesis of prostaglandins, prostacyclin, and thromboxanes. Concomitant use increases the risk of dose-dependent adverse effects, particularly gastrointestinal ulceration, bleeding, and perforation, as well as renal impairment, due to additive inhibition of protective prostaglandins in the gut and kidney. Clinically, this combination may result in acute kidney injury, anemia from occult gastrointestinal bleeding, or life-threatening perforation, especially in elderly patients or those with pre-existing renal disease or peptic ulcer history."
"Bevantolol, a beta-1 selective adrenergic receptor antagonist, reduces cardiac output and suppresses renin release, thereby lowering blood pressure. Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes, leading to decreased synthesis of vasodilatory prostaglandins and enhanced sodium and water retention. The net effect is an attenuation of bevantolol's antihypertensive efficacy, potentially resulting in elevated blood pressure and reduced cardiovascular protection."
"Betaxolol, a beta-1 selective adrenergic receptor antagonist, may reduce the antihypertensive efficacy of naproxen, a nonsteroidal anti-inflammatory drug (NSAID). Naproxen inhibits cyclooxygenase (COX) enzymes, leading to decreased synthesis of vasodilatory prostaglandins (e.g., prostacyclin) in the renal and vascular endothelium. This can result in sodium and fluid retention, increased systemic vascular resistance, and blunting of the blood pressure-lowering effects of beta-blockers like betaxolol, potentially compromising hypertension control."
"Co-administration of rizatriptan, a selective 5-HT1B/1D receptor agonist, with sertraline, a selective serotonin reuptake inhibitor (SSRI), increases the risk of serotonin syndrome due to additive serotonergic effects. This potentially life-threatening condition is characterized by neuromuscular excitation, autonomic instability, and altered mental status. Patients should be monitored for symptoms such as hyperthermia, rigidity, myoclonus, and tachycardia, especially during initiation or dose escalation."
"Paroxetine, a selective serotonin reuptake inhibitor (SSRI), inhibits the metabolism of rizatriptan, a triptan used for migraine, via CYP1A2 and possibly other pathways, leading to increased rizatriptan plasma concentrations. This elevates the risk of serotonin syndrome, a potentially life-threatening condition characterized by neuromuscular abnormalities, autonomic instability, and altered mental status. Clinically, patients may experience symptoms such as hyperthermia, rigidity, myoclonus, and tachycardia, requiring prompt recognition and management."
"The combination of rizatriptan, a serotonin 5-HT1B/1D receptor agonist, and ziprasidone, an atypical antipsychotic with serotonergic activity (5-HT2A antagonist and weak serotonin reuptake inhibition), may increase the risk of serotonin syndrome. Serotonin syndrome is a potentially life-threatening condition characterized by neuromuscular excitation, autonomic instability, and altered mental status. This additive serotonergic effect occurs through overlapping mechanisms, including enhanced 5-HT1A and 5-HT2A receptor activation."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SUMATRIPTAN; NAPROXEN SODIUM vs RIZATRIPTAN BENZOATE, answered by our medical review team.
SUMATRIPTAN; NAPROXEN SODIUM is a 5-HT1 Agonist that works by Sumatriptan is a selective 5-HT1B/1D receptor agonist, causing vasoconstriction of cranial blood vessels and inhibition of trigeminal nerve transmission. Naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.. RIZATRIPTAN BENZOATE is a 5-HT1 Agonist that works by Selective serotonin 5-HT1B/1D receptor agonist; binds with high affinity to 5-HT1B and 5-HT1D receptors, leading to vasoconstriction of intracranial blood vessels and inhibition of trigeminal nerve transmission, thereby reducing migraine-associated neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SUMATRIPTAN; NAPROXEN SODIUM and RIZATRIPTAN BENZOATE depend on the specific clinical indication. These are both 5-HT1 Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SUMATRIPTAN; NAPROXEN SODIUM is: Sumatriptan 85 mg / naproxen sodium 500 mg orally at onset of migraine; may repeat once after 2 hours if needed, not to exceed 2 tablets in 24 hours.. The standard adult dose of RIZATRIPTAN BENZOATE is: 5-10 mg orally at onset of migraine; may repeat after 2 hours if headache recurs; maximum 30 mg in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SUMATRIPTAN; NAPROXEN SODIUM and RIZATRIPTAN BENZOATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SUMATRIPTAN; NAPROXEN SODIUM is classified as Category D/X. Sumatriptan: Limited data; no increased risk of major congenital malformations observed in cohort studies. Avoid use in third trimester due to potential uterine vasoconstriction an. RIZATRIPTAN BENZOATE is classified as Category D/X. Rizatriptan is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, rizatriptan was not teratogenic in rats o. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.